Molecular Cancer Therapeutics  Targeting the PI3-Kinase Pathway in Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Molecular Cancer Therapeutics 7, 1013-1024, May 1, 2008. Published Online First April 29, 2008;
doi: 10.1158/1535-7163.MCT-07-0177
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Material
Right arrow All Versions of this Article:
1535-7163.MCT-07-0177v1
7/5/1013    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Petalidis, L. P.
Right arrow Articles by Collins, V. P.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Petalidis, L. P.
Right arrow Articles by Collins, V. P.

Research Articles: Therapeutics, Targets, and Development

Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data

Lawrence P. Petalidis1, Anastasis Oulas2,3, Magnus Backlund6, Matthew T. Wayland4, Lu Liu1, Karen Plant1, Lisa Happerfield1, Tom C. Freeman5, Panayiota Poirazi2 and V. Peter Collins1

1 Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom; 2 Institute for Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas; 3 Graduate Program in Molecular Biology and Biomedicine, Department of Biology, University of Crete, Heraklion, Crete, Greece; 4 Cambridge Centre for Neuropsychiatric Research, University of Cambridge, Cambridge, United Kingdom; 5 Division of Pathway Medicine, College of Medicine, University of Edinburgh, Edinburgh, Scotland, United Kingdom; and 6 Department of Oncology-Pathology, Karolinska Hospital, Karolinska Institute, Stockholm, Sweden

Requests for reprints: Panayiota Poirazi, Institute for Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Vassilika Vouton, P.O. Box 1385, GR 711 10 Heraklion, Crete, Greece. E-mail: poirazi{at}imbb.forth.gr

Abstract

Histopathologic grading of astrocytic tumors based on current WHO criteria offers a valuable but simplified representation of oncologic reality and is often insufficient to predict clinical outcome. In this study, we report a new astrocytic tumor microarray gene expression data set (n = 65). We have used a simple artificial neural network algorithm to address grading of human astrocytic tumors, derive specific transcriptional signatures from histopathologic subtypes of astrocytic tumors, and asses whether these molecular signatures define survival prognostic subclasses. Fifty-nine classifier genes were identified and found to fall within three distinct functional classes, that is, angiogenesis, cell differentiation, and lower-grade astrocytic tumor discrimination. These gene classes were found to characterize three molecular tumor subtypes denoted ANGIO, INTER, and LOWER. Grading of samples using these subtypes agreed with prior histopathologic grading for both our data set (96.15%) and an independent data set. Six tumors were particularly challenging to diagnose histopathologically. We present an artificial neural network grading for these samples and offer an evidence-based interpretation of grading results using clinical metadata to substantiate findings. The prognostic value of the three identified tumor subtypes was found to outperform histopathologic grading as well as tumor subtypes reported in other studies, indicating a high survival prognostic potential for the 59 gene classifiers. Finally, 11 gene classifiers that differentiate between primary and secondary glioblastomas were also identified. [Mol Cancer Ther 2008;7(5):1013–24]


Footnotes

Grant support: Cancer Research UK, UK Medical Research Council, The Jacqueline Seroussi Memorial Foundation for Cancer Research, Samantha Dickson Research Trust, Ludwig Institute for Cancer Research, General Secretariat for Research and Technology, Hellas (project PENED 03ED842), and EMBO Young Investigator Program.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: L. P. Petalidis, A. Oulas, P. Poirazi, and V.P. Collins contributed equally to this work.

7 Supplementary material for this article is available at Molecular Cancer Therapeutics Online (http://mct.aacrjournals.org/).

8 The source code for the ANN and visualization methods is available from http://www.imbb.forth.gr/people/poirazi/software.html.

Received 3/13/07; revised 1/11/08; accepted 3/26/08.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.